BAX and colorectal cancer: We conducted this study to test the hypothesis that TGFBR2 or BAX mononucleotide mutations in colorectal cancer were associated with altered tumor behavior (beyond MSI), utilizing a database of 1072 stage I to IV colorectal cancers in two prospective cohort studies.